Conference Coverage
In the second segment of this roundtable series, the panel discusses the importance of safe sampling in biomarker testing.
In the first segment of this roundtable series, the panel discusses the initial steps in NSCLC diagnosis and treatment.
In the seventh part of this roundtable series, the panel discusses surgical preparations and considerations.
In the sixth segment of this roundtable series, the discusses how multidisciplinary teams monitor and manage AEs.
In the fifth segment of the roundtable series, experts discuss advances in adjuvant, neoadjuvant and perioperative treatment.
In the third part of this roundtable discussion, experts share insights on the decision-making process surrounding treatment
Dr. Osarogiagbon discussed the impact of the lung cancer screening program on diagnosis rates across the Mississippi Delta.
In the second segment of this roundtable discussion, experts discuss considerations surrounding biospies and biomarkers.
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Thorsten Füreder, MD, shares insights from the NSCLC cohort of the phase 2 trial.
Dr. Liu explains how these two studies are shaping standards of care and the treatment landscape in SCLC.
The phase 3 study compared the efficacy data of benmelstobart plus anlotinib with that of pembrolizumab monotherapy.
Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Xiuning Le, MD, PhD, discusses the phase 3 trial, which follows the SOHO-01 trial of the oral TKI.
Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Learn more about outcomes from the first minimal residual disease analysis of the DART trial.
Dr. Archambault discusses the safety and effectiveness of cemiplimab plus chemotherapy for first-line treatment of aNSCLC.
Latest News
Physician's Weekly
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.